The phase 3 SUCCESSOR-2 trial has shown that adding Mezigdomide to a treatment combination of Carfilzomib and Dexamethasone significantly improves progression-free survival in patients with relapsed or refractory Multiple Myeloma. The study included patients who had received at least one previous line of therapy, including treatment with Lenalidomide and anti-CD38 antibodies, a group that often has limited treatment options after relapse.
Mezigdomide is an oral CELMoD (cereblon E3 ligase modulator) designed to target the cell’s protein-degradation system. By modifying the cereblon pathway, the drug promotes the breakdown of key proteins that help myeloma cells survive. In the randomized, multicenter trial, patients receiving the combination of mezigdomide, carfilzomib, and dexamethasone experienced better disease control compared with those receiving carfilzomib and dexamethasone alone. Researchers also evaluated additional outcomes, including overall survival, overall response rate, and quality of life.
The safety profile of the regimen was consistent with previous studies of CELMoD drugs. The most commonly reported side effects included neutropenia, infections, anemia, and thrombocytopenia. Despite these adverse events, investigators believe the results highlight the potential of mezigdomide as a next-generation therapy beyond traditional immunomodulatory drugs such as Revlimid. Experts say the treatment could provide a new option for patients whose disease has progressed after standard therapies. Full data from the SUCCESSOR-2 trial are expected to be presented at an upcoming medical conference and shared with global regulatory authorities.